OncoMatch/Clinical Trials/NCT05830500
Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma
Is NCT05830500 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies Anlotinib Hydrochloride Capsule for medullary thyroid cancer.
Treatment: Anlotinib Hydrochloride Capsule — This is a real world study aiming to observe the efficacy and safety of Anlotinib capsules in patients with advanced medullary thyroid carcinoma, and to summarize the treatment experience in a broad population of patients.
Check if I qualifyExtracted eligibility criteria
Cancer type
Thyroid Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: VEGFR inhibitor (anlotinib, vandetanib, cabozantinib, lenvatinib, sunitinib, sorafenib)
Patients who have previously used anlotinib hydrochloride capsules or similar Vascular Endothelial Growth Factor- Tyrosine Kinase Inhibitor (VEGFR-TKI) small molecule drugs, such as vandetanib, cabozantinib, lenvatinib, sunitinib, sorafenib, etc.;
Lab requirements
Blood counts
Hemoglobin ≥85g/L; ANC ≥1.5×10^9/L; Platelet ≥80×10^9/L (no transfusion within 14 days)
Kidney function
Serum creatinine ≤1.5x ULN or Creatinine clearance rate ≥60 ml/min
Liver function
Total bilirubin (TBIL) ≤1.5x ULN; ALT and AST ≤2.5x ULN; if liver metastasis, ALT and AST ≤5x ULN
Major organ functions meet the following criteria within 7 days prior to the treatment: ... Blood routine examination ... Hemoglobin (Hb) ≥85g/L; Absolute Neutrophil Count (ANC) ≥1.5×10^9/L; Platelet (PLT) ≥80×10^9/L; ... Biochemical examination ... Total bilirubin (TBIL) ≤1.5 times the upper limit of normal (ULN); Alanine transferase (ALT) and Aspartate transferase (AST) ≤2.5×ULN; If accompanied by liver metastasis, ALT and AST ≤5×ULN; Serum creatinine (Cr) ≤1.5×ULN or Creatinine clearance rate (CCr) ≥60ml/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify